Versartis Boosts IPO Plan by Half
March 19, 2014
Versartis, a startup working on treatments for growth hormone deficiency, boosted the expected size of the IPO it plans later this week by nearly 50 percent.
The Redwood City company led by CEO Jeffrey Cleland now says it could raise a total of $144.9 million, including shares set aside for underwriters, up from last week's $100.5 million target.
Versartis now plans to sell 6 million shares at a price range of between $19 and $21. Last week it said it would sell 4.6 million shares at between $16 and $19.
Versartis has raised about $144 million since it was founded in 2008. Its biggest shareholders are New Leaf Venture Partners (24.4 percent stake), Index Ventures (22.4 percent), Advent Life Sciences (16.3 percent), Aisling Capital (11.9 percent) and Sofinnova Ventures (6.8 percent).
It plans to list on the NASDAQ under the symbol VSAR.
The company is still pre-revenue, according to its SEC filing, accumulating a loss of $53.7 million since December 2008. Click here to see Jeff Cleland ring the closing bell at the NASDAQ after the IPO.
About
The Alliance of Chief Executives is an active community of business leaders that focuses on deep strategic exchanges, challenging existing assumptions and generating fresh ideas.
Contact Us
Alliance of Chief Executives, LLC
2175 N. California Blvd.,
Suite 605
Walnut Creek, CA 94596
- 925-942-2400 Office
- 925-956-4424 Fax
- Email: info@allianceofCEOs.com
Newsletter
Subscribe to our newsletter and stay up to date with the latest Alliance news!
About
The Alliance of Chief Executives is an active community of business leaders that focuses on deep strategic exchanges, challenging existing assumptions and generating fresh ideas.
Newsletter
Subscribe to our newsletter and stay up to date with the latest Alliance news!
Recent Member News
Member Resources
Contact Us
2175 N. California Blvd., Suite 605
Walnut Creek, CA 94596
925-942-2400 Office
925-956-4424 Fax
Email: info@allianceofCEOs.com
2026 © Alliance of Chief Executives, LLC
